Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.

Latest News

  • 15 Sep
    2017

    Pivotal Phase III data for Diurnal’s Infacort® published in Clinical Endocrinology

    Paper is published on an open access basis

    Read More

  • 06 Sep
    2017

    Results for the year ended 30 June 2017

    First marketing authorisation expected H2 2017

    Read More

  • 06 Sep
    2017

    Diurnal announces grant of first US patent for Chronocort®

    Composition of matter patent provides protection until 2033 in key US market.

    Read More